Taris Biomedical Inc. drummed up $18.3 million in its latest funding round.
Lexington, Mass.-based company said the equity-based B round will support its lidocaine delivery technology developed at MIT to treat bladder conditions.
Third Rock Ventures, a new backer for the company, led the round, and previous investors Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners also participated in the financing.
Syneron Medical Ltd. (NSDQ:ELOS) reported a 250 percent increase in sales during 2010, as the aesthetic device maker began to see some payoff from its 2009 acquisition of Candela Corp.
Syneron, a Yokneam, Israel aesthetic device company reported $189 million in sales during the year ending on Dec. 31, 2010, compared to $54 million for the same period last year. Much of that increase is directly attributed to products the company picked up in its $65 million acquisition of Candela Corp. in Sept. 2009.
Pressure BioSciences boosts Q3 sales, cuts losses
Pressure BioSciences Inc. (NSDQ:PBIO) reported a loss of $693,000, or 26 cents per share, on revenue of $372,000 during the three months ended Sept. 30. That compares with losses of about $776,000, or 35 cents per share, on revenue of $317,427 during the same period last year.
MassDevice Network
@MassDevice
LinkedIn
YouTube